Want to see HK:2126 full AI Analyst Report?
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.40 - HK$4.18
Previous CloseN/A
Volume104.00K
Average Volume (3M)1.94M
Market Cap
HK$925.48M
Enterprise ValueHK$507.99M
Total Cash (Recent Filing)HK$392.02M
Total Debt (Recent Filing)HK$254.85M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding416,883,360
10 Day Avg. Volume1,067,750
30 Day Avg. Volume1,936,389
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross-margin ImprovementThe sharp 2025 revenue rebound, alongside improved gross margin, indicates stronger commercialization and better economics for the company’s therapy portfolio. If sustained, this combination can expand operating leverage, support reinvestment in clinical programs, and improve the path toward eventual profitability.
Reduced Operating Cash BurnThe substantial reduction in operating cash burn suggests improved cost control and/or working-capital dynamics. Although cash generation remains negative, a smaller recurring outflow preserves financial flexibility for longer and gives management more time to scale revenue and progress toward break-even.
Manageable Debt LeverageDebt does not currently appear to be the primary balance-sheet constraint, as leverage remains below one times equity. This provides more flexibility than a highly levered structure to fund development and commercialization, while reducing the immediate burden of debt-related financial risk.
Bears Say
Deep And Persistent UnprofitabilityDespite stronger revenue and narrower losses, the company remains far from operating break-even. A deeply negative net margin means commercial growth is not yet translating into sustainable earnings, leaving profitability dependent on further scale, cost improvement, or successful product expansion.
Ongoing Negative Free Cash FlowPersistent negative free cash flow limits the company’s ability to finance research, clinical development, and commercialization internally. Until cash generation turns positive, JW Therapeutics may need continued access to external capital, which can constrain strategic flexibility and increase funding risk.
Equity Erosion From Accumulated LossesOngoing losses have weakened the capital base over time, as reflected in material equity erosion and very negative returns on equity. Continued deterioration could reduce financial resilience and make future investment, funding, or expansion decisions more dependent on raising additional capital.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.40 and its highest was HK$4.18 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$925.48M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 152 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2026. The company reported -HK$0.14 earnings per share for the quarter.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,883,360 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.14 in its last earnings report. Following the earnings report the stock price went up 4.651%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.65%
12-Months-Change
Fundamentals
Return on Equity
-66.16%
Trailing 12-Months
Asset Growth
-38.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―